{"prompt": "['Cara Therapeutics, Inc., CR845', 'IND 123140, SN 0072', 'Cara Therapeutics, Inc.', 'Confidential', 'Page 39 of 92', 'CR845-CLIN3103', '0.04 M isotonic acetate buffer, pH 4.5. The composition of the CR845 solution is CR845', '(free base), acetic acid, sodium acetate trihydrate, sodium chloride, hydrochloric acid, and', 'water for injection.', 'Matching placebo (0.04M isotonic acetate buffer, pH 4.5) will be provided in 2-mL glass', 'vials containing a minimum extractable volume of 1.3 mL. The composition of the', 'placebo buffer solution is acetic acid, sodium acetate trihydrate, sodium chloride,', 'hydrochloric acid, and water for injection. The placebo buffer is identical to the buffer', 'solution used in the CR845 solution and has identical appearance as the solution', 'containing the active ingredient. The placebo buffer solution will be packaged, stored,', 'and shipped identically to the CR845 solution.', '6.4.2.2', 'Packaging, Labeling, and Storage Stability of Study Drug', 'Study drug will be shipped at 15\u00b0C to 30\u00b0C. Temperature will be monitored during', 'shipment and verified and recorded in the pharmacy log by the pharmacist upon arrival at', 'the site. The vials must be stored at a temperature ranging from 15\u00b0C to 30\u00b0C upon', 'receipt and the temperature will be monitored accordingly.', 'For the Double-blind Treatment Period vials will be packaged (blinded) in boxed kits (also', 'blinded) containing 40 vials per box (4 extra vials for backup). Kits will be labeled with', 'patient ID number and kit number. A single box of vials will be assigned to a patient.', 'For the Open-label Extension Phase, vials will be packaged in boxed kits containing', '12 vials per box. Kits will be labeled with patient ID number and kit number. A single', 'box of vials will be assigned to a patient.', 'Labeling of the vials and kits will conform to the regulations required by each country.', '6.4.2.3', 'Individual Dose Labeling', 'One syringe will be prepared for each patient on each dosing day. Syringes and syringe', 'labels will be provided. Refer to the ISF for details.', '6.4.3', 'Drug Accountability', 'All supplies will be maintained under adequate security by the pharmacist or approved', 'staff at the investigational site. At the end of each injection, the used vials will be stored', 'until the study monitor performs accountability. Details of study drug accountability and', 'return are provided in the ISF.', 'The Sponsor (or delegated person) will be permitted, at intervals and upon request during', 'the study, to check the supplies, storage and dispensing procedures, and records.', '6.4.4', 'Method of Assigning Patients to Treatment Groups', 'Before the start of the study, computer-generated randomization schedules will be', 'prepared. Randomization will be performed using an interactive voice or web response', 'system (IVRS/IWRS). Patients will be randomized in a 1:1 ratio to receive either CR845', '10 September 2019', 'Version 2.2']['Cara Therapeutics, Inc., CR845', 'IND 123140, SN 0072', 'Cara Therapeutics, Inc.', 'Confidential', 'Page 40 of 92', 'CR845-CLIN3103', '0.5 mcg/kg IV or matching placebo IV during the Double-blind Treatment Period.', 'Patients will be stratified into 2 strata according to their use or non-use of concomitant', 'medications to treat their itch during the pre-randomization week (Run-in Period) as well', 'as the presence or absence of specific medical conditions. These specific medical', 'conditions include:', 'History of fall or fracture (related to fall)', 'Confusional state or mental status change or altered mental status or disorientation', 'Gait disturbance or movement disorder', 'All eligible patients will receive CR845 at a dose of 0.5 mcg/kg starting on Day 1 of the', 'Open-label Extension Phase.', '6.4.5', 'Preparation of CR845', 'In the Double-blind Phase of the study, a single vial of study drug will be used for each', \"patient. Each patient's prescription dry body weight will not exceed 135.0 kg.\", 'In the Open-label Extension Phase of the study, 1 vial of CR845 will be used for patients', 'with a prescription dry body weight <135.0 kg. For patients with a prescription dry body', 'weight >135.0 kg, 2 vials of CR845 will be used to ensure that the full volume of study', 'drug can be prepared. Further details will be provided in the ISF.', 'Information on the study drug preparation can be found in the Pharmacy Manual.', '6.4.6', 'Management of Missed Doses', 'If a patient misses a dialysis visit and the planned dose of CR845 for that visit, dosing', 'should resume at the next dialysis visit.', 'Contact the Medical Monitor if patient compliance or safety is of concern.', '6.4.7', 'Treatment Compliance', 'Patient compliance with study drug is documented as part of standard procedures at the', 'dialysis units where study drug is administered.', '6.4.8', 'Blinding', 'During the Double-blind Treatment Period, patients, Investigators, study staff, and the', 'Sponsor will be blinded to study drug assignment.', 'For medically urgent or emergent situations that necessitate knowledge of study drug', 'assignment for patient management, the blind may be broken via the IVRS/IWRS. Except', \"for when patient's care requires the treatment assignment immediately, the Medical\", 'Monitor should be contacted prior to breaking the blind. The Sponsor and Medical', 'Monitor will receive a report whenever a patient blind is broken.', '10 September 2019', 'Version 2.2']\n\n###\n\n", "completion": "END"}